Global Anti-Infectives Market to Reach $103 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Anti-Infectives market. The global anti-infectives market is projected to exceed $103 billion by the year 2015. Factors driving sales include introduction of novel therapeutics for drug-resistant bacteria, increasing incidence of severe fungal infections, potential launch of new antiviral agents, and introduction of new drugs in the HIV market.

Anti-Infectives: A Global Strategic Business Report

Anti-infectives are indicated for the treatment of infections caused by bacteria, fungi, protozoa, prions, and parasites. Anti-infectives market mainly includes antibacterials, anti-virals, anti-fungals, and vaccines. Other causative agents responsible for developing infectious disorders include Chlamydiae, Mycoplasmas, Worms, Rickettsiae, Helminths, and Yeast.

Antibacterials represent the largest segment of anti-infectives market globally, as stated by a new market research report on anti-infectives. Among the anti-bacterials class, sales is led by Cephalosporins, followed by Macrolides, Fluoroquinolones, and Penicillins. Anti-virals represents another major anti-infective drug class. Some of the major growth drivers for anti-virals include increased awareness of the disease and its progression, development of novel drug classes, limited generic competition, increased R&D investments fuelled by the growth of drug resistance among patients, and reduction of R&D costs through genomics. Anti-viral drugs are also expected to register the fastest growth rate, compared to the other drug classes, including ant-bacterials, anti-fungals, and others such as vaccines.

Key players profiled in the report include Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma Inc., AstraZeneca Plc, Bayer HealthCare AG, Bristol-Myers Squibb Co., Boehringer Ingelheim, Cubist Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline Plc, F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi-Aventis SA, Schering-Plough Corp., and Wyeth Pharmaceuticals Inc., among others.

The report titled "Anti-Infectives: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of anti-infectives market by therapeutic class, growth drivers, growth inhibitors, research and development, product introductions/, product approvals and recent industry activity. The study provides sales for regions including US, Japan, Europe and Rest of World. The report also analyzes the market by therapeutic classes, including antibacterials, antivirals, antifungals, and others. Anti-bacterials are further broken down by drug classes such as Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others.

For more details about this comprehensive market research report, please visit -

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website